Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trevi TherapeuticsTRVI -2.49%22 OCF Yield % is -2.05 as of Aug. 10, 2026. GuruFocus rates TRVI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Trevi Therapeutics ranks better than 70.4% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Trevi Therapeutics OCF Yield % Related Terms
Trevi Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Trevi Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Trevi Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trevi Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Trevi Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trevi Therapeutics (TRVI) has a OCF Yield % of -2.05 as of Aug. 10, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Trevi Therapeutics and its competitors. According to the industry distribution chart, Trevi Therapeutics ranks #417 out of 1409 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Trevi Therapeutics' OCF Yield % too high?
Trevi Therapeutics' current OCF Yield % is -2.05. Based on the distribution chart, Trevi Therapeutics ranks #417 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Trevi Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Trevi Therapeutics' OCF Yield % compare to IMNM and VERA?
According to the Biotechnology industry distribution chart, Trevi Therapeutics ranks #417 out of 1409 companies for OCF Yield %. This puts Trevi Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Trevi Therapeutics and its competitors. Trevi Therapeutics's current OCF Yield % is -2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trevi Therapeutics stock overvalued right now?
Trevi Therapeutics (TRVI) has a current OCF Yield % of -2.05. The current OCF Yield % is -2.05. Trevi Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Trevi Therapeutics (TRVI), the current OCF Yield % is -2.05 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score
Get the complete analysis for TRVI
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRVI has been successfully added to your 
